Watkins DB - Search Results

1

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.

Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tang C, et al. Among authors: watkins db. Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30. Leuk Lymphoma. 2011. PMID: 21718141

2

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients.

Kok CH, Leclercq T, Watkins DB, Saunders V, Wang J, Hughes TP, White DL. Kok CH, et al. Among authors: watkins db. Leukemia. 2014 Mar;28(3):702-5. doi: 10.1038/leu.2013.329. Epub 2013 Nov 6. Leukemia. 2014. PMID: 24192813 No abstract available.

3

OCT1 and imatinib transport in CML: is it clinically relevant?

Watkins DB, Hughes TP, White DL. Watkins DB, et al. Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9. Leukemia. 2015. PMID: 26122430 Review.

4

Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.

Ross DM, Watkins DB, Hughes TP, Branford S. Ross DM, et al. Among authors: watkins db. Clin Chem. 2008 Sep;54(9):1568-71. doi: 10.1373/clinchem.2008.105916. Epub 2008 Jul 18. Clin Chem. 2008. PMID: 18641042

5

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis.

Watkins DB, Hughes TP, White DL, D'Andrea RJ. Watkins DB, et al. Leukemia. 2013 Feb;27(2):489-90. doi: 10.1038/leu.2012.193. Epub 2012 Jul 13. Leukemia. 2013. PMID: 22791379 No abstract available.

6

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL. Nievergall E, et al. Among authors: watkins db. Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22. Leukemia. 2016. PMID: 26898188 Clinical Trial.

7

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP. Kok CH, et al. Among authors: watkins db. Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195. Blood Adv. 2019. PMID: 31126916 Free PMC article.

8

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation.

Kok CH, Watkins DB, Leclercq T, D'Andrea RJ, Hughes TP, White DL. Kok CH, et al. Among authors: watkins db. Leukemia. 2013 Jun;27(6):1427-30. doi: 10.1038/leu.2013.47. Epub 2013 Feb 15. Leukemia. 2013. PMID: 23411466 No abstract available.

9

TINEA NIGRA. REPORT OF A CASE IN FLORIDA.

WATKINS DB. WATKINS DB. Dermatol Trop Ecol Geogr. 1964 Jul-Sep;30:173-5. doi: 10.1111/j.1365-4362.1964.tb06099.x. Dermatol Trop Ecol Geogr. 1964. PMID: 14230957 No abstract available.

10

CADMIUM SULFIDE IN THE MANAGEMENT OF TINEA VERSICOLOR.

WATKINS DB. WATKINS DB. Dermatol Trop Ecol Geogr. 1964 Apr-Jun;28:111-4. doi: 10.1111/j.1365-4362.1964.tb06032.x. Dermatol Trop Ecol Geogr. 1964. PMID: 14201324 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page